Olaparib for triple-negative breast cancer without BRCA changes
Treatments studied
Part of Cancer clinical trials.
This phase 2 trial studies olaparib (a targeted cancer medicine) in people with recurrent or metastatic triple-negative breast cancer who do not have certain BRCA1/2 gene changes. It aims to see whether the drug can slow cancer growth in this specific tumor type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18–70 with triple-negative breast cancer that has returned and spread
- Your tumor does NOT have a BRCA1/2 mutation and does NOT have BRCA1 promoter methylation
- You’ve had no more than 2 prior anti-cancer treatment lines for the recurrence/spread
- You have at least one measurable tumor spot on scans (evaluable lesion)
- Your overall health is fairly good (ECOG 0–1) and you’re expected to live at least 3 months
- You have not taken chemotherapy, radiation, targeted anti-cancer therapy, or similar treatments in the last 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
This trial tests a combination of two drugs, QL1706 (an immunotherapy) and olaparib (a targeted therapy), for people with a specific type of advanced breast cancer called triple-negative that has a DNA repair problem (HRD). It may be an option if you've had 1 or 2 prior treatments but haven't tried similar drugs before.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
This Phase 2 trial tests temozolomide by itself or together with olaparib in people with triple-negative breast cancer that has a specific tumor marker (MGMT promoter methylation). It may help shrink tumors by targeting cancer cells in a way that standard treatment may not fully achieve.
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.